Early Assessment of Efficacy and Safety of Biologics in Pediatric Allergic Diseases: Preliminary Results from a Prospective Real-World Study.
Lucia CaminitiFrancesca GallettaSimone Foti RandazzesePaolo BarracoStefano PassanisiAntonella GambadauroGiuseppe CrisafulliMariella ValenziseSara MantiPublished in: Children (Basel, Switzerland) (2024)
Our findings validate omalizumab and dupilumab as effective and safe therapeutic options for managing moderate-to-severe allergic diseases in children and adolescents.
Keyphrases